ReNeuron Group plc (LON:RENE)‘s stock had its “buy” rating reissued by stock analysts at Stifel Nicolaus in a report released on Thursday, November 9th. They presently have a GBX 13 ($0.17) price target on the stock.
Separately, N+1 Singer reaffirmed a “corporate” rating on shares of ReNeuron Group in a research report on Monday, October 9th.
ReNeuron Group (LON:RENE) traded down GBX 0.03 ($0.00) during mid-day trading on Thursday, reaching GBX 1.95 ($0.03). The company’s stock had a trading volume of 1,114,132 shares, compared to its average volume of 2,210,000. ReNeuron Group has a 52 week low of GBX 1.58 ($0.02) and a 52 week high of GBX 3.67 ($0.05).
About ReNeuron Group
ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company’s products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP).
Receive News & Ratings for ReNeuron Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group plc and related companies with MarketBeat.com's FREE daily email newsletter.